On April 26, DIAN Diagnostic entered into an exclusive strategic cooperation agreement respectively with Roche Group (hereinafter referred to as “Roche”) and Foundation Medicine, Inc. (hereinafter referred to as “FMI”), to jointly accelerate the progression of individualized diagnosis and treatment of tumor in China.
The relevant agreement provides that DIAN Diagnostics will become an exclusive partner of FMI regardingthe comprehensive genome sequencing analysis service of tumor (CGP) in clinical market of China, to launch advanced products for comprehensive genome sequencing analysis, establish DIAN FMI lab, construct standardized whole-process quality management system, realize the application of FMI’s FoundationOne®, FoundationOne®Heme and FoundationACT® products in China (excluding Macao Hong Kong and Taiwan), and seek for appropriate therapy for patients with cancer. Roche will work together with DIAN to accelerate the commercialization of the aforesaid products in Chinese clinical market.
All of the three parties will make full use of their own advantageous resources to promote the clinical application of international leading comprehensive genome sequencing analysis service in the field of tumor diagnosis and treatment in China, and to develop new standards on individualized diagnosis and treatment of tumors, so as to improve the overall efficiency of tumor diagnosis and treatment.
FoundationOne® is the first product launched under this cooperation framework, which is also the first comprehensive genome sequencing analysis service (CGP) for patients with solid tumors in China. With only one single detection, FoundationOne® will present an analysis report of complete genome map which will provide comprehensive data support for clinicians to make diagnosis and treatment decisions, and help them develop targeted diagnosis and therapy, so as to prolong the life cycle of patients and improve their life quality.
Established in Delaware, USA, and listed at NASDAQ, FMI is a bioinformatics company dedicated to guiding the precise treatment of tumors through in-depth understanding and analysis of tumor-related gene changes, who provides a series of complete genome sequencing to detect the molecular mutations of patients with tumors and provides targeted therapy, immunotherapy and clinical trials related to it. The purpose of FMI’s molecular information platform is to serve the needs of clinicians, academic researchers and pharmaceutical developers, so as to promote the scientific development of daily care of patients and molecular diagnostics in the field of tumor.
“Individualized diagnosis and treatment of tumors is becoming the critical topic in the field of precision medicine in China, and will lead the future development direction of China’s medical industry. Over the years, DIAN Diagnostics has been actively building the precision diagnostic platforms, including the gene sequencing platform covering reproductive, tumor and genetic disease diagnosis, as well as the biological mass spectrometry platform. We’re fully aware that we need to cooperate with those who share the same aspiration in order to promote the development of precision medicine in China and to improve China’s clinical diagnosis level. That’s why we join hands with Roche and FMI to jointly promote the application of CGP in China’s clinical diagnosis and treatment.” said Chen Haibin, the chairman of DIAN Diagnostics.
“Roche has well realized that precise treatment cannot go without more precise diagnostics. As a leader in the field of tumor and individualized medicine, it’s our duty to benefit Chinese patients as quickly as possible with advanced comprehensive genome sequencing analysis service. We’re very pleased to have reached strategic cooperation with DIAN Diagnostics, a third-party medical diagnostic service institutions leading in China, to introduce advanced CGP and provide technical support for Chinese people to achieve the goal of ‘conquering cancer as soon as possible’”, said Zhou Hong, general manager of Roche China.
Malignant tumor is a major disease that seriously threatens human health and social development. As specifically required by the strategic plan of “healthy China”: by 2030, the overall 5-year survival rate of cancer in China should be further increased by 15%. Premier Li Keqiang has clearly proposed the goal of “gathering dominant powers to tackle difficult and high-incidence cancers”, and the requirement that we should strive to overcome difficulties affecting people’s health in adherence to people-centered development thought.
The introduction of CGP for solid tumors will establish new standards on individualized diagnosis and treatment of tumors in China, and will gradually form the big data of China’s tumors, which will provide support for the long-term tackling of tumor diagnosis and treatment, and keep China’s diagnosis and treatment of solid tumors in line with international standards to enter an individualized era with high efficiency and precision.
The CGP launched during this cooperation will make use of the international leading NGS technology to detect all of the four mutations in tumor-related genes and identify clinically relevant mutations missed by other detection methods and related therapy. This analysis method has been verified and so far, has benefited more than 180 thousand patients. In the future, DIAN Diagnostics will also introduce advanced technology from FMI and is expected to launch two more analytical service products- FoundationOne®Heme and FoundationACT® in 2019.
DIAN Diagnostics is recognized as one of the first national demonstration centers for clinical application of gene detection technology and one of the first national pilot units of high-throughput gene sequencing technology for tumor diagnosis and treatment project. Through this cooperation, DIAN will on the basis of the existing NGS technical platform, focus on building DIAN FMI lab by introducing international leading comprehensive genome sequencing analysis technology and process system from FMI, and will, relying on DIAN’s strengths and ecology in the in vitro diagnosis industry as well as Roche's global business expertise, promote the clinical application of international advanced sequencing technologies in China, contribute to clinical decision-making and provide much more therapy with more appropriateness for patients with tumors; moreover, DIAN will introduce a standardized and systematic whole-process quality management system for laboratories, and reinforce the coordination with domestic regulatory authorities in developing the standards of comprehensive genome sequencing service industry in line with China's national conditions; upon commencement of the strategic cooperation with Roche and FMI, DIAN will give play to the advantages of all the three parties in more fields in the future, and co-write a new chapter to help China’s precision diagnostics achieve great leap forward development.
